To the Editor:

The emergence of a novel coronavirus, SARS-CoV-2, causing a disease in humans termed COVID-19, has left the medical community with many open questions in the evaluation and treatment of these patients.[@bib0001], [@bib0002], [@bib0003] Regarding the signature respiratory injury that is an important aspect of this disease, there appear to be 2 different phenotypes: type "L," with low elastance (high compliance), low lung weight, and low recruitability; and type "H," with high elastance (low compliance), high lung weight, and high recruitability.[@bib0004] ^,^ [@bib0005] It is not clear if these 2 phenotypes represent different manifestations of the same disease or evolution of one type into the other, but it is possible that treating every patient according to "traditional" acute respiratory distress syndrome (ARDS) guidelines might worsen outcomes in some of these patients.[@bib0004] ^,^ [@bib0005]

For example, current ARDS management includes treating hypoxemia by titrating up positive end-expiratory pressure. However, increasing positive end-expiratory pressure also decreases right ventricular preload and, in patients with low alveolar recruitability, increases both right ventricular afterload and the transpulmonary pressure gradient. The transpulmonary gradient is the pressure distending the lung parenchyma and is mathematically equal to the alveolar pressure (plateau pressure) minus the pressure in the pleural space (aka the pleural pressure). Notably, the transpulmonary gradient is a critical determinant of "lung stress" and damage in both spontaneously breathing[@bib0006] and mechanically ventilated patients.[@bib0007] Even a healthy lung is quickly damaged in the presence of a high transpulmonary gradient.[@bib0008] Conversely, knowledge of the transpulmonary gradient can be used to deliver goal-directed, lung-protective ventilation,[@bib0007] ^,^ [@bib0009] with upper limits of 15- to- 20 cm H~2~O for healthy patients and 10- to- 12 cm H~2~O for ARDS patients.[@bib0009] In fact, such transpulmonary pressure-guided ventilation has been associated with decreased mortality in patients with ARDS.[@bib0010] ^,^ [@bib0011]

The pleural pressure component of the transpulmonary gradient is typically measured by using an esophageal manometer. But since esophageal manometry is not available in many sites treating COVID-19 patients, an alternative means of measuring the transpulmonary gradient using more ubiquitous equipment could prove valuable. In the past, multiple authors have reported that respiratory variation of central venous pressure (CVP) accurately reflects variation in transpulmonary pressure in mechanically ventilated patients (including ARDS) and with different ventilation modes.[@bib0012], [@bib0013], [@bib0014] Consequently, this readily available cardiovascular monitor may provide actionable insight into COVID-19 pulmonary physiology.

Central venous pressure monitoring with careful observation of the CVP waveform during the respiratory cycle provides diagnostic clues that are not evident from the digital (mean) value of CVP ([Fig 1](#fig0001){ref-type="fig"} ).[@bib0015] ^,^ [@bib0016] In COVID-19 patients, these respirophasic changes in CVP could be used to guide pulmonary support. For instance, in nonintubated patients, the finding of large peak-to-trough swings in CVP suggest that the patient is generating large, potentially injurious transpulmonary pressure gradients, a process that clinicians may wish to stop with intubation and controlled ventilation. Similarly, after intubation, some COVID-19 patients are initially placed on triggered modes of ventilation (eg, pressure support), which involve patient respiratory effort. In that context, detection of large respirophasic swings in CVP again suggests underlying, proportionally large swings in pleural pressure that are additive to the positive pressure delivered through the pressure support mode. For instance, an intubated patient receiving a standard pressure support of 15 cm H~2~O observed to have CVP peak-to-trough swings of --10 mmHg (--13.6 cm H~2~O) is producing a net transpulmonary pressure equal to the following: 15 cm H~2~O -- (--13.6 cm H~2~O) = ∼29 cm H~2~O, which is significant because transpulmonary gradients greater than 10 cm H~2~O are known to worsen alveolar injury in already damaged lungs.[@bib0009] Thus, among intubated COVID-19 patients receiving triggered modes of ventilation, monitoring CVP changes with respiration could help determine when to escalate pulmonary support from assisted to controlled (passive) ventilation.[@bib0010] ^,^ [@bib0011] A possible (although theoretical) use of ΔCVP to guide respiratory support and ventilation is provided in [Table 1](#tbl0001){ref-type="table"} .Fig. 1Central venous pressure variation during quiet and forceful breathing. *Top*, during quiet spontaneous ventilation, there is a small variation in mean central venous pressure (CVP) from approximately 12 mmHg at end-expiration (1) to 9.5 mmHg during inspiration (2). *Bottom,* during forceful or deep breathing, the respiratory variation in CVP increases markedly from approximately 16 mmHg at end-expiration (1) to 8 mmHg during inspiration (2).Fig 1Table 1Possible Use of ΔCVP to Adjust Respiratory Support and Ventilation in Different Ventilation Modes.Table 1Fully Spontaneous VentilationAssisted VentilationFully Controlled VentilationHow to estimate TPPAbsolute value of ΔCVPΔP~aw~[\*](#tb1fn1){ref-type="table-fn"} -- ΔCVPΔP~aw~ -- ΔCVPTPP threshold when respiratory support may need to be escalated15-20 cmH~2~O (∼11-15 mmHg)10-12 cmH~2~O (∼8-9 mmHg)10-12 cmH~2~O (∼8-9 mmHg)Respiratory escalation to consider, especially if PaO~2~/F~I~O~2~ worseningIncrease supplemental oxygen and/or attempt prone positioning in attempt to minimize diaphragmatic effortIf the above fails, consider endotracheal intubationIncrease sedation (+/- add paralytic) and transition to fully controlled ventilationPlace in prone positioningEnsure patient is on fully passive ventilationPlace in prone positioning- V-V ECMO if PaO~2~/F~I~O~2~ \< 100 and worsening despite passive ventilation and proning[^1][^2]

In summary, the viral epidemic has pushed healthcare systems to their limits. Patients infected with SARS-CoV-2 will present with different pathophysiologic derangements and different phenotypes that may require different therapeutic approaches. Careful observation of the respiratory variation in the CVP tracing may be a useful diagnostic tool to guide appropriate ventilatory support.

Conflict of Interest {#sec0001}
====================

None.

[^1]: Abbreviations: ΔCVP, peak-to-trough respirophasic gradient in central venous pressure; ΔP~aw~, driving pressure; operationally equal to: plateau pressure -- PEEP; F~I~O~2~/ PaO~2~, the ratio between fractional inspired O2 concentration and partial pressure of oxygen, TPP, transpulmonary pressure; V-V ECMO, veno-venous extracorporeal membrane oxygenation.

[^2]: Considering that the true plateau pressure might be difficult to estimate during pressure support ventilation, the value of pressure support can be used in lieu of ΔP~aw~.
